CA
NZ
UK
AU
IND
US
…
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -16.54M | -27.13M | -19.93M | -32.15M | -33.32M |
| Net income | -14.45M | -25.56M | -18.48M | -31.47M | -33.32M |
| Selling general administrative | 28.29M | 36.38M | 30.45M | 34.31M | 27.14M |
| Selling and marketing expenses | 28.31M | 28.35M | 20.95M | 18.22M | 16.54M |
| Gross profit | 42.80M | 41.49M | 35.27M | 25.77M | 16.05M |
| Reconciled depreciation | 1.88M | 1.63M | 1.51M | 1.52M | 0.84M |
| Ebit | -20.51M | -28.70M | -21.37M | -32.82M | -34.01M |
| Ebitda | -18.63M | -27.07M | -19.85M | -31.30M | -33.17M |
| Depreciation and amortization | 1.88M | 1.63M | 1.51M | 1.52M | 0.84M |
| Non operating income net other | - | - | - | - | -0.07M |
| Operating income | -18.63M | -27.07M | -19.85M | -31.30M | -33.17M |
| Other operating expenses | 90.68M | 94.52M | 79.11M | 77.59M | 64.73M |
| Interest expense | 0.00M | 0.06M | 0.07M | -0.85M | 0.08M |
| Interest income | - | - | - | 0.85M | 0.08M |
| Net interest income | 0.00M | -0.06M | -0.07M | -0.85M | -0.08M |
| Income tax expense | -2.09M | -1.57M | -1.44M | -0.68M | 0.22M |
| Total revenue | 72.05M | 67.45M | 59.26M | 46.29M | 31.56M |
| Total operating expenses | 61.42M | 68.56M | 55.13M | 57.07M | 49.23M |
| Cost of revenue | 29.25M | 25.96M | 23.98M | 20.52M | 15.50M |
| Total other income expense net | 2.09M | -0.06M | -0.07M | -0.85M | -0.07M |
| Net income from continuing ops | -18.62M | -27.13M | -19.93M | -32.15M | -33.32M |
| Net income applicable to common shares | -16.54M | -27.13M | -19.93M | -32.15M | -33.32M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 54.96M | 54.06M | 57.84M | 38.36M | 40.25M |
| Intangible assets | 0.51M | 0.67M | 0.86M | 1.08M | 1.31M |
| Other current assets | 2.45M | 2.97M | 1.86M | 1.15M | 1.00M |
| Total liab | 26.51M | 25.39M | 26.11M | 21.93M | 19.80M |
| Total stockholder equity | 28.46M | 28.67M | 31.73M | 16.42M | 20.45M |
| Deferred long term liab | - | - | - | - | 3.87M |
| Other current liab | 9.49M | 7.34M | 6.48M | 6.13M | 4.42M |
| Common stock | 0.07M | 0.07M | 0.07M | 0.06M | 0.06M |
| Capital stock | 0.07M | 0.07M | 0.07M | 0.06M | 0.06M |
| Retained earnings | -190.46M | -185.49M | -168.95M | -141.82M | -121.90M |
| Other liab | - | 3.96M | 4.35M | 4.44M | 3.87M |
| Other assets | - | 0.50M | 0.72M | 0.62M | 0.76M |
| Cash | 27.32M | 20.24M | 28.02M | 16.50M | 18.81M |
| Total current liabilities | 20.62M | 17.87M | 17.61M | 16.48M | 15.06M |
| Current deferred revenue | 0.20M | 0.16M | 0.16M | 0.28M | 0.17M |
| Net debt | -24.05M | -15.98M | -23.32M | -14.86M | -17.09M |
| Short term debt | 0.70M | 0.70M | 0.55M | 0.62M | 0.85M |
| Short long term debt total | 3.28M | 4.26M | 4.70M | 1.64M | 1.72M |
| Other stockholder equity | 218.84M | 214.09M | 200.61M | 158.19M | 142.28M |
| Property plant equipment | - | 6.32M | 7.36M | 3.21M | 4.66M |
| Total current assets | 49.53M | 46.57M | 48.91M | 32.22M | 33.52M |
| Net tangible assets | - | 28.00M | 30.87M | 16.42M | 19.13M |
| Net receivables | 5.23M | 8.48M | 5.23M | 2.69M | 2.17M |
| Inventory | 14.53M | 14.68M | 13.60M | 11.68M | 11.54M |
| Accounts payable | 10.23M | 9.68M | 10.42M | 9.45M | 9.63M |
| Accumulated other comprehensive income | -0.00M | -0.00M | -0.00M | -0.00M | -2.79M |
| Common stock total equity | - | 0.07M | 0.07M | 0.06M | 0.06M |
| Retained earnings total equity | - | -185.49M | -168.95M | -141.82M | -121.90M |
| Non currrent assets other | 0.38M | 0.50M | 0.72M | 0.62M | 0.76M |
| Non current assets total | 5.43M | 7.49M | 8.94M | 6.14M | 6.73M |
| Capital lease obligations | 3.28M | 4.26M | 4.70M | 1.64M | 1.72M |
| Long term debt total | - | - | - | - | 0.02M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.33M | -0.41M | -0.17M | -0.05M | -0.32M |
| Change to liabilities | 0.11M | 1.21M | 2.21M | 3.95M | 6.57M |
| Total cashflows from investing activities | -0.33M | -0.41M | -0.17M | -0.25M | -1.77M |
| Net borrowings | -0.08M | -0.11M | -0.05M | 9.32M | -0.21M |
| Total cash from financing activities | 7.65M | 36.09M | 8.65M | 16.88M | -0.09M |
| Change to operating activities | -0.78M | -1.28M | 0.38M | -0.77M | 0.64M |
| Net income | -16.54M | -27.13M | -19.93M | -32.15M | -33.32M |
| Change in cash | -7.78M | 11.52M | -2.12M | -3.80M | -22.77M |
| Begin period cash flow | 28.22M | 16.70M | 18.81M | 22.62M | 45.39M |
| End period cash flow | 20.44M | 28.22M | 16.70M | 18.81M | 22.62M |
| Total cash from operating activities | -15.10M | -24.16M | -10.60M | -20.44M | -20.91M |
| Issuance of capital stock | 7.75M | 26.74M | 4.86M | 6.77M | 0.00M |
| Depreciation | 1.88M | 1.63M | 1.51M | 1.52M | 0.84M |
| Other cashflows from investing activities | -0.33M | -0.41M | 0.12M | 0.54M | -0.13M |
| Change to inventory | -1.08M | -1.92M | -0.15M | -3.29M | -2.45M |
| Change to account receivables | -3.32M | -2.58M | 2.06M | -0.04M | 1.11M |
| Sale purchase of stock | 7.75M | 36.23M | 8.97M | 7.84M | -0.40M |
| Other cashflows from financing activities | -0.08M | 9.38M | 4.07M | 10.39M | 0.51M |
| Change to netincome | 5.88M | 6.35M | 9.61M | 9.54M | 6.30M |
| Capital expenditures | 0.33M | 0.41M | 0.14M | 0.75M | 1.45M |
| Change receivables | -3.32M | -2.58M | 2.06M | -0.04M | 1.11M |
| Cash flows other operating | -1.20M | -1.21M | -0.37M | -0.30M | 0.04M |
| Cash and cash equivalents changes | -7.78M | 11.52M | -2.12M | -3.80M | -22.77M |
| Change in working capital | -6.01M | -4.19M | 3.69M | 0.43M | 5.19M |
| Stock based compensation | 5.74M | 6.20M | 6.94M | 7.17M | 6.37M |
| Other non cash items | -0.17M | -0.71M | -0.64M | 0.35M | 0.14M |
| Free cash flow | -15.43M | -24.57M | -10.74M | -21.19M | -22.36M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
310 388 6706
106
| Name | Title | Year Born |
|---|---|---|
| Mr. Frank Louis Jaksch Jr. | Co-Founder & Chairman | 1968 |
| Mr. Robert N. Fried | CEO & Director | 1960 |
| Ms. Brianna Gerber | Sr. VP of Fin., VP of Investor Relations & Interim CFO | 1980 |
| Dr. Andrew Shao Ph.D. | Sr. VP of Global Regulatory & Scientific Affairs | NA |
| Heather Van Blarcom | Sr. VP of Legal & Corp. Sec. | NA |
| Alex Worsham | VP of Global Marketing & Communications | NA |
| Mr. Fadi Karam | Chief Marketing Officer | NA |
| David Kroes | Sr. VP of People Matters | NA |
| Ms. Chu Yan | Managing Director of Asia Pacific | NA |
| Tom Shumaker | Managing Director of LifeSci Advisors | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...